King George 3d and porphyria.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to N Roth.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The limitations of traditional multifocal lenses to replace normal ocular accommodation are well known. The recent development of progressive addition lenses circumvent many of those problems, furnishing smoothly varying power in desired amounts for various distances and allowing freedom from distracting lines. Optical characteristics, screening considerations, prescribing and fitting requirements, and the advantages and limitations of progressive addition lenses are discussed.
Neuromuscular control deficits are supposed to contribute to the development of osteoarthritis (OA). Pain measurements were performed to clarify whether nociceptive afferents differ between OA patients and healthy subjects. Thermal pain thresholds were significantly higher in OA subjects as compared to controls, but there was no difference in perceptual thresholds after electrical stimulation. Lateralization, gender, site of OA changes, previous operations, or medication did not affect these findings.
PURPOSE: To evaluate the 24-week impact of saquinavir-enhancing antiretroviral therapy on viral replication in patients previously treated with nucleoside analogues with or without prior saquinavir hard-gel capsules (HGC). METHOD: Patients were randomized in three groups to receive the following: Group 1-nelfinavir (750 mg tid), saquinavir soft-gel capsule (SGC) (800 mg tid), and stavudine (40 mg bid); Group II-ritonavir (400 mg bid), saquinavir-SGC (400 mg bid), and stavudine (40 mg bid); or Group III-delavirdine (400 mg tid), saquinavir-SGC (800 mg tid), and stavudine (40 mg bid). Viral loads, CD4 count, and safety were assessed over a 24-week period with an additional 6-month follow-up. RESULTS: 73 patients received randomized therapy; 14 of whom were SQV naïve, with a median baseline viral load of 3.6 log(10) and a CD4 count of 370 cells/mm(3). By 6 months, the median decreases in plasma viral loads were 0.26, 0.71, and 0.29 log(10) copies/mL for groups I, II, and III, respectively. The median increases in CD4 counts, for groups I, II, and III, were 52, 40, and 69 cells/mm(3) at 6 months, respectively. Changes in viral load and CD4 counts at 6 months and 1 year were not significantly different between the treatment groups. More patients discontinued therapy in the ritonavir arm (35%) for drug intolerance or toxicity compared to either the nelfinavir or delavirdine arms (15% and 5%, respectively). In a multivariate analysis, baseline viral load, younger age, and baseline saquinavir resistance were significantly associated with detectable viral load at 24 weeks. CONCLUSION: The use of antiretroviral agents that pharmacokinetically boost saquinavir levels has a modest benefit in saquinavir-experienced patients.
Explore the source record for details and available documents.
On the basis of contemporary knowledge on close functional connections between respiratory and cardiovascular afferents a computerized experimental device was developed by means of which central information processing can be studied in dependence on respiration phase and the level of baroreceptor activity. In all the examined parameters (time of motor reaction of two hands, latency of eye-lid reflex) the greatest changes were observed at maximum baroreceptor activity. These changes were clearly distinguished by direction during the phases of inhalation and exhalation. Such effect is probably based on the fact that the influence of cardiovascular afferents on the level of central activity is modulated in respiration rhythm through the mechanism of breath "gating" of postsynaptic STN structures.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.